- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02191163
Efficacy of Antistax® in Improving Microcirculation of the Skin in the Leg in Patients Suffering From Chronic Venous Insufficiency
July 15, 2014 updated by: Boehringer Ingelheim
A 17 Week, Randomised, Double-blind, Placebo Controlled Cross-over Trial to Evaluate the Efficacy of Antistax® Film Coated Tablets (Extr. Vitis Vinifera Siccum), 360 mg/Day p.o. in Improving Microcirculation of the Skin in the Leg of Male and Female Patients Suffering From Chronic Venous Insufficiency
Study to determine the efficacy and safety of Antistax® film coated tablets in improving microcirculation of the skin in the leg of patients with chronic venous insufficiency (CVI)
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
71
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female
- >= 18 years of age
- CVI I or CVI II (without expanded trophic disturbances)
- Willing and able to give written informed consent in accordance to Good Clinical Practice and local legislation prior to participation in the study
Exclusion Criteria:
Concomitant disease(s) exclusion criteria:
- Decompensated cardiac insufficiency
- Edema not due to venous disease of the legs (e.g. latent cardiac insufficiency, renal insufficiency, lymph edema, etc)
- Peripheral arterial disease (ankle/arm pressure index < 0.9)
- Current acute phlebitis or thrombosis
- Renal insufficiency (Serum creatinine > 1.5 mg/dl)
- Liver disease (SGPT (ALAT) > 3x upper limit of normal)
- Other diseases: insulin-dependent diabetes mellitus, neuropathies, hyper- or hypocalcaemia, malignancies
- Anamnestic indications of diabetic microangiopathy or polyneuropathy
- Drug and/or alcohol abuse
- Pregnant or nursing women or inadequate birth control methods (this applies to females of childbearing potential only)
- Severe climacteric complaints or changes in, or initiation with post-menopausal hormone replacement therapy within the last 3 months
- Immobility
- Avalvulie
- Klippel-Trénaunay-Weber-Syndrome (Naevus varicosis osteohypertrophicus, Haemangiectasia hypertrophicans)
- State after pulmonary embolism
- Recognized hypersensitivity to the trial drug ingredients
- Current florid venous ulcus
- Clinical indication for a necessary, specific phlebologic acute treatment, e.g. compressive treatment, phlebectomy, etc.
Previous treatment(s) exclusion criteria:
- Treatment with venous drugs within the last 4 weeks
- Changes in, or initiation with, treatment with theophylline, diuretics, cardiac glycosides, ACE inhibitors or calcium antagonists within the last 8 days
Concomitant treatment/non-drug therapy exclusion criteria:
- Other venous drugs apart from the trial medication
- Compression bandages
- Venous surgery of the leg used for the fluxmetry
- Extensive use (i.e. on more than a total of 6 days during the entire trial) of laxatives which affect fluid or electrolyte balance
- Major surgery requiring full anesthesia
Other exclusion criteria:
- Previously studied under this protocol
- Participation in another clinical trial within the previous 90 days or during the present study
- Patients considered as mentally ill as well as unable to work or with limited working ability, or unable (or only partially able) to follow the spoken or written explanations concerning the trial
- Patients in a bad general health state according to the investigator's judgment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
|
Experimental: Antistax®
1 x 360 mg for 42 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from baseline in the resting flux
Time Frame: Baseline, after 6 weeks of treatment
|
measured in the frequency range 10-37 kHz on the skin of the inside lower leg using the Laser Doppler Fluxmetry
|
Baseline, after 6 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from baseline in the resting flux
Time Frame: Baseline, after 3 weeks of treatment
|
measured in the frequency range 10-37 kHz
|
Baseline, after 3 weeks of treatment
|
Changes in the resting flux
Time Frame: Baseline, after 3 and 6 weeks of treatment
|
measured in the frequency range <10 kHz
|
Baseline, after 3 and 6 weeks of treatment
|
Changes in the combined resting fluxes (<37 kHz)
Time Frame: Baseline, after 3 and 6 weeks of treatment
|
Baseline, after 3 and 6 weeks of treatment
|
|
Changes in the transcutaneous oximetry (TcPO2)
Time Frame: Baseline, after 3 and 6 weeks of treatment
|
measured on the inside lower leg of the more CVI-affected leg
|
Baseline, after 3 and 6 weeks of treatment
|
Change from baseline in the calf circumference of the most affected leg
Time Frame: Baseline, after 3 and 6 weeks of treatment
|
Baseline, after 3 and 6 weeks of treatment
|
|
Change from baseline in the ankle circumference of the most affected leg
Time Frame: Baseline, after 3 and 6 weeks of treatment
|
Baseline, after 3 and 6 weeks of treatment
|
|
Change from baseline in the subjective symptoms of CVI measured by Visual Analogue Scales (VAS)
Time Frame: Baseline, after 3 and 6 weeks of treatment
|
Baseline, after 3 and 6 weeks of treatment
|
|
Global efficacy assessment by patient on a 4-point verbal rating scale (VRS)
Time Frame: after 6 weeks of treatment
|
after 6 weeks of treatment
|
|
Global efficacy assessment by investigator on a 4-point VRS
Time Frame: after 6 weeks of treatment
|
after 6 weeks of treatment
|
|
Number of patients with adverse events
Time Frame: up to 16 weeks
|
up to 16 weeks
|
|
Number of patients with clinically relevant changes in laboratory values
Time Frame: Baseline, up to 16 weeks
|
Baseline, up to 16 weeks
|
|
Number of patients with clinically significant changes in vital signs
Time Frame: Baseline, up to 16 weeks
|
Baseline, up to 16 weeks
|
|
Global tolerability assessment by investigator on a 4-point VRS
Time Frame: after 6 weeks of treatment
|
after 6 weeks of treatment
|
|
Global tolerability assessment by patient on a 4-point VRS
Time Frame: after 6 weeks of treatment
|
after 6 weeks of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2002
Primary Completion (Actual)
August 1, 2002
Study Registration Dates
First Submitted
July 15, 2014
First Submitted That Met QC Criteria
July 15, 2014
First Posted (Estimate)
July 16, 2014
Study Record Updates
Last Update Posted (Estimate)
July 16, 2014
Last Update Submitted That Met QC Criteria
July 15, 2014
Last Verified
July 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1138.3
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Venous Insufficiency
-
Value Outcomes Ltd.Alfasigma S.p.A.RecruitingChronic Venous Disease | Chronic Insufficiency VenousCzechia
-
State Budgetary Healthcare Institution, National...CompletedEndothelial Dysfunction | Venous Insufficiency of Leg | Venous Insufficiency (Chronic)(Peripheral)Russian Federation
-
GCS Ramsay Santé pour l'Enseignement et la RechercheVivactis M2ResearchRecruitingSuperficial Venous InsufficiencyFrance
-
C. R. BardEnrolling by invitation
-
Medtronic EndovascularCompletedVenous Insufficiency of LegUnited Kingdom, Denmark, Germany, Netherlands
-
Hancock Jaffe Laboratiores, IncSyntactx; AXIOM Real Time MetricsRecruitingDeep Venous Insufficiency (Diagnosis)United States
-
Medtronic EndovascularCompleted
-
Angiodynamics, Inc.Completed
-
Shannon HernonGalway ClinicUnknownChronic Venous InsufficiencyIreland
-
Virginia Commonwealth UniversityCompletedChronic Venous InsufficiencyUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States